Pratia Expands Clinical Research Network with CRC Acquisition in Czech Republic and Slovakia
Pratia, renowned as a leading Research Site Network which spans across eight countries globally, has revealed plans to enhance its clinical trial capabilities by expanding operations into Slovakia and the Czech Republic through its acquisition of the Clinical Research Centre (CRC). This strategic maneuver, announced on January 8, 2025, is designed to emphasize patient access to innovative treatment options while augmenting the existing business model in these regions.
Łukasz Bęczkowski, the Chief Operating Officer of Pratia, expressed enthusiasm about incorporating CRC into Pratia's extensive network, stating, "We are thrilled to welcome CRC into the Pratia family. This strategic move marks a significant milestone in Pratia's mission to increase innovative treatment access for patients." This acquisition aims to build upon the existing strengths of CRC, which boasts an extensive network of over 140 investigators dedicated to patient healthcare and clinical research across a variety of therapeutic areas including oncology.
Through this merger, both organizations anticipate increased opportunities for collaboration amongst cooperating investigators as well as CRC staff, potentially enhancing the overall research output. Radek Špatenka, who serves as the Country Head for Czechia and Slovakia, further elaborated that the synergy forged between Pratia’s site network and home care services presents a clear advantage in conducting hybrid clinical trials, particularly those featuring decentralized trial components (DCT).
By welcoming CRC into its portfolio, Pratia significantly broadens its reach, gaining access to a new pool of over one million potential patients. This strategic expansion solidifies Pratia's standing in important therapeutic fields, including oncology, marking a substantial step towards enhancing patient care and treatment development.
The co-founder of CRC, Lucie Špatenkova, remarked, "Together, we are able to deepen our impact in clinical research while maintaining CRC's established reputation in the industry. We aim to provide unmatched research capabilities and improve patient outcomes." This acquisition aligns with Pratia's commitment to driving innovation and delivering exceptional value to the pharmaceutical sector.
Pratia's pedigree as a prominent research site network is built upon a proven track record, having conducted over 3,000 clinical trials across diverse therapeutic areas since its establishment in 2012. They remain laser-focused on partnering with pharmaceutical companies, clinical research organizations, and healthcare professionals to forge improvements in medical knowledge and enhance patient outcomes.
The Clinical Research Centre (CRC), with over a decade of experience in clinical trial processes, distinguishes itself as a leading clinical trial network in the Czech Republic and Slovakia. Leveraging a robust network of more than 160 investigators, CRC facilitates high-quality clinical research across various medical specialties, ensuring rigorous and credible testing of new drug protocols in both outpatient and home-care settings.
As the landscape of clinical trials continues to evolve, this acquisition positions Pratia at the forefront of clinical research innovation, enhancing its capability to serve diverse patient populations and fulfill the increasing demand for cutting-edge medical solutions. The integration into CRC’s established network not only strengthens its existing functions but opens doors to new possibilities in the rapidly advancing field of clinical research.
Łukasz Bęczkowski, the Chief Operating Officer of Pratia, expressed enthusiasm about incorporating CRC into Pratia's extensive network, stating, "We are thrilled to welcome CRC into the Pratia family. This strategic move marks a significant milestone in Pratia's mission to increase innovative treatment access for patients." This acquisition aims to build upon the existing strengths of CRC, which boasts an extensive network of over 140 investigators dedicated to patient healthcare and clinical research across a variety of therapeutic areas including oncology.
Through this merger, both organizations anticipate increased opportunities for collaboration amongst cooperating investigators as well as CRC staff, potentially enhancing the overall research output. Radek Špatenka, who serves as the Country Head for Czechia and Slovakia, further elaborated that the synergy forged between Pratia’s site network and home care services presents a clear advantage in conducting hybrid clinical trials, particularly those featuring decentralized trial components (DCT).
By welcoming CRC into its portfolio, Pratia significantly broadens its reach, gaining access to a new pool of over one million potential patients. This strategic expansion solidifies Pratia's standing in important therapeutic fields, including oncology, marking a substantial step towards enhancing patient care and treatment development.
The co-founder of CRC, Lucie Špatenkova, remarked, "Together, we are able to deepen our impact in clinical research while maintaining CRC's established reputation in the industry. We aim to provide unmatched research capabilities and improve patient outcomes." This acquisition aligns with Pratia's commitment to driving innovation and delivering exceptional value to the pharmaceutical sector.
Pratia's pedigree as a prominent research site network is built upon a proven track record, having conducted over 3,000 clinical trials across diverse therapeutic areas since its establishment in 2012. They remain laser-focused on partnering with pharmaceutical companies, clinical research organizations, and healthcare professionals to forge improvements in medical knowledge and enhance patient outcomes.
The Clinical Research Centre (CRC), with over a decade of experience in clinical trial processes, distinguishes itself as a leading clinical trial network in the Czech Republic and Slovakia. Leveraging a robust network of more than 160 investigators, CRC facilitates high-quality clinical research across various medical specialties, ensuring rigorous and credible testing of new drug protocols in both outpatient and home-care settings.
As the landscape of clinical trials continues to evolve, this acquisition positions Pratia at the forefront of clinical research innovation, enhancing its capability to serve diverse patient populations and fulfill the increasing demand for cutting-edge medical solutions. The integration into CRC’s established network not only strengthens its existing functions but opens doors to new possibilities in the rapidly advancing field of clinical research.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.